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Background and Purpose: There is concern about the increase of radiation-induced malignancies with the application of modern 
radiation treatment techniques such as intensity-modulated radiotherapy (IMRT) and proton radiotherapy. Therefore, X-ray scat-
ter and neutron radiation as well as the impact of the primary dose distribution on secondary cancer incidence are analyzed. 
Material and Methods: The organ equivalent dose (OED) concept with a linear-exponential and a plateau dose-response curve 
was applied to dose distributions of 30 patients who received radiation therapy of prostate cancer. Three-dimensional conformal 
radiotherapy was used in eleven patients, another eleven patients received IMRT with 6-MV photons, and eight patients were 
treated with spot-scanned protons. The treatment plans were recalculated with 15-MV and 18-MV photons. Secondary cancer risk 
was estimated based on the OED for the different treatment techniques. 
Results: A modest increase of 15% radiation-induced cancer results from IMRT using low energies (6 MV), compared to conventional 
four-field planning with 15-MV photons (plateau dose-response: 1%). The probability to develop a secondary cancer increases 
with IMRT of higher energies by 20% and 60% for 15 MV and 18 MV, respectively (plateau dose-response: 2% and 30%). The use of 
spot-scanned protons can reduce secondary cancer incidence as much as 50% (independent of dose-response). 
Conclusion: By including the primary dose distribution into the analysis of radiation-induced cancer incidence, the resulting 
increase in risk for secondary cancer using modern treatment techniques such as IMRT is not as dramatic as expected from earlier 
studies. By using 6-MV photons, only a moderate risk increase is expected. Spot-scanned protons are the treatment of choice in 
regard to secondary cancer incidence. 
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Entstehung von Zweittumoren nach Radiotherapie: der Einfluss von IMRT und Protonentherapie 
Hintergrund und Ziel: Durch den Einsatz moderner Bestrahlungstechniken, wie intensitätsmodulierte Strahlentherapie (IMRT) und 
Protonentherapie, könnte die Anzahl strahleninduzierter Zweittumoren zunehmen. Deswegen wird der Einfluss von Röntgen- und 
Neutronenstreustrahlung (Tabelle 2) sowie der primären Dosisverteilung auf die Inzidenz von Sekundärtumoren quantifiziert. 
Material und Methodik: Das Konzept der Organäquivalentdosis (OED) mit einer linear-exponentiellen und einer Plateau-Do-
sis-Wirkungs-Beziehung wurde auf die Dosisverteilungen von 30 Patienten mit Prostatakarzinom (Tabelle 1) angewendet. Von 
den 30 Patienten wurden elf mit konformaler Radiotherapie, elf mit 6-MV-IMRT und acht mit Protonentherapie („spot-scanned“) 
behandelt. Die Bestrahlungspläne wurden für 15-MV- und 18-MV-Photonen neu optimiert. Die OED für die verschiedenen Bestrah-
lungstechniken (Tabelle 3, Abbildung 1) ist proportional zur Sekundärtumorwahrscheinlichkeit.
Ergebnisse: Wird anstatt konventioneller Vier-Felder-Planung (15-MV-Photonen) ein 6-MV-IMRT-Plan verwendet, steigt die Anzahl 
strahleninduzierten Tumoren um etwa 15% an (Plateau-Dosis-Wirkungs-Beziehung: 1%). Wird allerdings eine höhere Photonen-
energie für die IMRT verwendet (Abbildung 1), steigt die Wahrscheinlichkeit, einen Zweittumor zu entwickeln, um 20% für 15 MV bzw. 
um 60% für 18 MV an (2% bzw. 30% für eine Plateau-Dosis-Wirkungs-Beziehung). Verwendet man Protonentherapie („spot-scanned“) 
für die Behandlung, kann die Sekundärtumorinzidenz, unabhängig von der Dosis-Wirkungs-Beziehung, um 50% vermindert werden.
Schlussfolgerung: Wird neben der Streu- und Neutronenstrahlung auch die primäre Dosisverteilung in die Analyse der Sekun-
därtumorinzidenz mit einbezogen, steigt das Risiko für einen Zweittumor beim Einsatz der IMRT nicht so dramatisch an, wie in 
früheren Studien vorhergesagt. Verwendet man ausschließlich 6-MV-Photonen für die IMRT, wird das Sekundärtumorrisiko nur 
leicht erhöht. Der Einsatz der Protonentherapie kann in Bezug auf die Entstehung von Zweittumoren gegenüber der Photonen-
therapie von Vorteil sein. 
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Introduction
In developed countries, more than half of all cancer patients 
receive radiotherapy at some stage in the management of their 
disease [7]. However, a radiation-induced secondary malig-
nancy can be the price of success, if the primary cancer is cured 
or at least controlled [1, 2]. 
With the application of new radiation treatment modali-
ties such as intensity-modulated radiotherapy (IMRT) or pro-
ton radiotherapy [20] increased cancer cure rates are expected. 
However, with the application of these treatment techniques 
also a larger number of secondary cancers is expected. The 
reason for this increased secondary malignancy incidence is 
the substantial increase in beam-on time of IMRT techniques 
to deliver the same target dose compared to conventional 
treatment techniques. In addition, during proton radiotherapy 
neutrons are created and could also have an impact on second-
ary cancer incidence. 
Several attempts have been made to estimate the risk of 
secondary cancer development after radiation therapy. One 
strategy is to estimate these risks based on measured X-ray 
and neutron leakage and computing the effective dose [3, 5, 8, 
19]. Estimates of the rate of induction of secondary malignan-
cies can then be obtained by using published risk data such as 
the ICRP recommendations. Such estimates usually result in 
an extremely high risk of secondary cancers after IMRT. The 
risk estimates vary between 2 to 8 depending on technique and 
energy compared to conventional radiotherapy. The draw-
back of these studies is the fact that the impact of the primary 
dose field is totally neglected and, hence, the estimate of the 
risk increase could be far too large. 
Another strategy is the estimation of cancer risk from 
the three-dimensional (3-D) dose distributions by applying 
radiation protection concepts including a cutoff dose to ac-
count for the reduced cancer risk at high dose [6, 11, 15]. 
Table 1. Treatment technique and prescribed dose listed for all 30 analyzed patients irradiated for prostate carcinoma. For photons also the treated 
MUs and for protons the number of applied protons are listed. CT: computed tomography; 3-D: three-dimensional conformal radiotherapy; IMRT: 
intensity-modulated radiotherapy; PRO: proton radiotherapy. 
Tabelle 1. Bestrahlungstechniken und verschriebene Dosen für alle 30 Patienten mit Prostatakarzinom. Für die Photonenpläne ist auch die Anzahl 
der bestrahlten MUs und für die Protonenpläne die Anzahl der verwendeten Protonen aufgelistet. CT: Computertomographie; 3-D: dreidimensio-
nale konformale Radiotherapie; IMRT: intensitätsmodulierte Radiotherapie; PRO: Protontherapie. 
Technique –  Number Energy Prescribed dose Total applied Total applied Total applied Number CT volume 
patient # of fields (MeV) (Gy/CGE) MU 6 MV MU 15 MV MU 18 MV of protons × 10–7 VCT  (cm
3) 
3-D – 1 4 15 76 –   9,888   8,753 – 14,646
3-D – 2 4 15 76 –   9,278   8,770 –   8,584
3-D – 3 4 15 76 –   9,667   9,037 – 20,978
3-D – 4 4 15 76 –   9,666   8,990 – 17,462
3-D – 5 4 15 76 –   9,542   8,974 – 10,498
3-D – 6 4 15 76 –   9,820   9,176 – 25,935
3-D – 7 4 15 76 –   9,897   9,678 – 19,914
3-D – 8 4 15 72 –   8,919   8,330 –   9,485
3-D – 9 4 15 72 –   8,913   8,462 – 11,160
3-D – 10 4 15 72 –   9,448   8,955 – 17,700
3-D – 11 4 15 67 –   8,663   8,096 – 22,248
IMRT – 1 5   6 76 15,846 12,844 12,806 – 16,151
IMRT – 2 5   6 76 19,076 15,276 15,162 –   8,584
IMRT – 3 5   6 76 14,136 12,122 11,666 – 11,861
IMRT – 4 5   6 72 26,892 23,400 16,164 – 12,231
IMRT – 5 5   6 70 22,155 16,065 15,855 – 15,373
IMRT – 6 5   6 76 14,706 11,704 12,008 – 15,355
IMRT – 7 5   6 72 15,588 12,528 12,204 – 32,155
IMRT – 8 5   6 72 15,660 13,068 12,528 – 11,517
IMRT – 9 5  6 72 15,948 12,240 11,736 – 20,730
IMRT – 10 5  6 76 16,454 12768 12,958 – 29,264
IMRT – 11 5  6 72 20,628 17,892 18,324 – 10,933
PRO – 1 2 214 74 – – –   9,140 10,003
PRO – 2 2 214 74 – – –   5,191 12,422
PRO – 3 2 214 74 – – –   4,742 10,239
PRO – 4 2 214 74 – – –   4,020 11,187
PRO – 5 2 214 74 – – –   7,870   9,142
PRO – 6 2 214 74 – – –   6,000 13,188
PRO – 7 2 214 74 – – – 11,320   8,914
PRO – 8 2 214 74 – – –   7,224   9,965
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Such approaches work not well for doses > 2–4 Gy and there-
fore the results from these studies must be interpreted with 
caution. 
In this report, we apply the concept of organ equivalent 
dose (OED) to dose-volume histograms (DVHs) of patients 
treated for prostatic carcinoma with 3-D conformal radiother-
apy, IMRT, and proton radiotherapy. Any dose distribution in 
an organ is equivalent and corresponds to the same OED, if it 
causes the same radiation-induced cancer incidence [16]. For 
low doses the OED is simply average organ dose, and hence 
the dose-response relationship for cancer induction here is 
with good precision a linear function of dose. However, for 
high doses a dose-response relationship extracted from sec-
ondary cancer incidence data after radiotherapy of Hodgkin’s 
disease is used [14].
We believe that the application of the OED concept to 
analyze 3-D dose distributions gives more realistic estimates 
of the potential risk for secondary cancer induction after the 
clinical application of different radiotherapy techniques.
Material and Methods 
Patients 
The patient treatments analyzed in this study consisted of 30 
patients irradiated for prostatic carcinoma. Eleven patients 
received 3-D conformal radiotherapy with a conventional 
four-field treatment technique using 15-MV photons deliv-
ered by a Varian Clinac CL2300 (Varian Medical Systems, 
Palo Alto, USA) in three phases and 1.8-Gy fractions. An-
other eleven patients were treated with IMRT and five irra-
diation fields using 6-MV photons using a sliding MLC (mul-
tileaf collimator) and a simultaneous boost technique with 
2.0-Gy fractions. Both groups of patients were irradiated at 
the Triemli Hospital Zürich, Switzerland, with a Varian Clin-
ac CL2300. The treatment plans of these patients were recal-
culated with 15-MV and 18-MV photons, respectively. Final-
ly, eight patients were irradiated with two lateral fields using 
spot-scanned protons. The latter patients were treated at the 
proton radiotherapy beam line at the Paul Scherrer Institute 
(PSI), Villigen, Switzerland, with a dose of 2.0 CGE (co-
balt-gray equivalent) per fraction which is 1.8 Gy assuming an 
RBE (relative biological effectiveness) 
of 1.1. An overview of the analyzed pa-
tients is given in Table 1 where also the 
prescribed dose is listed. Patients were 
chosen such that the average prescribed 
dose was similar in each group (3-D con-
formal radiotherapy: 73.8 Gy; IMRT: 
73.6 Gy; protons: 74 CGE). 
Volume Definition 
The total volume of a patient was di-
vided into the volume included in the 
CT (computed tomography) scan (VCT) 
and the volume not scanned (VnoCT). 
We define VnoCT by assuming a reference body weight of 
70 kg and a reference specific gravity of 1.07 [9, 20]: 
                 70,000   VnoCT = ––––––  cm
3–VCT  (1).                    1.07 
Photons 
We calculated the photon dose distributions using Eclipse 
7.3.10 (Varian Medical Systems, Palo Alto, USA). Differen-
tial DVHs of VCT were calculated from the 3-D dose distribu-
tions. For VnoCT, a homogeneous dose bath of phantom scat-
ter, collimator scatter and neutron dose was assumed. It is 
assumed that collimator scatter, including leakage dose Dcol
X 
and phantom scatter  Dpha
X  contribute equally to the total pho-
ton scatter dose [17]. The photon scatter dose was estimated 
from measured data for a point located 50 cm away from the 
center of a 10 × 10 cm2 treatment field at 10 cm depth and is 
listed in Table 2 for all photon energies [17]. Measured data on 
neutron dose from medical electron accelerators were taken 
from d’Errico et al. [4]. They measured the neutron dose 
equivalent for 15-MV and 18-MV photons at three different 
depths in water in the center of a 10 × 10 cm2 field and 50 cm 
off axis. For our estimates, we used the measured neutron 
equivalent dose values at 5 cm depth, since this corresponds 
approximately to the average neutron dose in depth (Figure 5 
of [4]). The neutron dose equivalents Daxis
N  and Doff–axis
N  are 
listed in Table 2. 
The 3-D conformal and IMRT photon dose distributions 
DCT
3D/IMRT  in VCT which were computed with the treatment-
planning system were then corrected for photon scatter and 
neutron dose:  
 DCT
3D/IMRT = DTPS
3D/IMRT + Daxis
N (2).
In VnoCT, the homogeneous dose for the 3-D conformal treat-
ments is 
 Dno
3D
CT = (Dcol
X + Dpha
X)MU3D+Doff-
N
axis (3),
where MU3D are the applied monitor units from Table 1. For 
the IMRT plans, the same amount of phantom scatter as in the 
3-D conformal plans was assumed. However, collimator scat-
Table 2. X-ray phantom scatter Dpha
X  [14], collimator scatter and leakage Dcol
X   [14], and neutron 
dose equivalent in Sv per treated MU for photons [4] and per treatment proton for proton 
radiotherapy [12]. 
Tabelle 2. Röntgenstreustrahlung (Phantomstreuung Dpha
X   [14]; Kollimatorstreuung und Leck-
strahlung Dcol
X   [14]) sowie Neutronenäquivalentdosis in Sv pro bestrahlte MU für Photonen [4] 
und pro bestrahltes Proton für Protonentherapie [12]. 
Radiation type 6-MV  15-MV  18-MV photons Protons
 photons photons photons
X-ray phantom scatter: Dpha
X  2 × 10–6 3 × 10–6 3 × 10–6 –
X-ray collimator scatter and leakage: Dcol
X  2 × 10–6 3 × 10–6 3 × 10–6 –
Neutrons on central axis: Daxis
N  0 1 × 10–5 4 × 10–5 6 × 10–14 
Neutrons 50 cm off axis: Doff-
N
axis  0 1 × 10
–6 1 × 10–5 2.5 × 10–14
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ter is produced throughout the whole irradiation time und 
must be weighted with the monitor units MUIMRT applied 
through IMRT: 
 D = DIMRTnoCT
X
pha
N
off-axis
IMRTX
col MU
3DMU+ D + D  (4).
Protons 
Proton dose was computed using the PSI proton treat-
ment-planning program [10, 12]. Differential DVHs of VCT 
were calculated from the 3-D dose distributions. Neutron dose 
was estimated using the measurements of Schneider et al. [13]. 
They measured neutron dose equivalent during proton radio-
therapy using spot-scanned protons and obtained a mean dose 
of 6 × 10–14 Sv/proton in the target and 2.5 × 10–14 Sv/proton in 
the patient volume excluding the target. Total neutron equiva-
lent dose for the different treatment plans was then computed 
by multiplying these values by the number of applied protons 
for the different treatment plans which are listed in Table 1. 
The 3-D dose distribution DCT
PRO  in VCT is then 
 D = DPROCT
N
axis
PRO
TPS + D  (5).
The homogeneous dose inside VnoCT is estimated as 
 D = D
PRO
noCT
N
no-axis  (6).
OED and Risk Calculation
The dose-response relationship for radiation-induced cancer 
is not very well known for doses > 2 Gy. There are two ex-
treme possibilities for the shape of the dose-response curves at 
high dose, a linear-exponential and a plateau curve [6]. It can 
be confidently expected that the real dose-response for cancer 
induction lies between these extreme cases [6]. Therefore, in 
the following we use both possibilities to estimate secondary 
cancer risk. 
By using the concept of OED for the whole body volume, 
the cancer incidence is directly proportional to OED: 
         I = I0 × OED (7),
where I is the secondary cancer incidence for solid cancers and 
I0 is the radiation-induced cancer risk for low dose from the 
atomic bomb survivors. It should be noted here, that all popula-
tion-related parameters, as, for example, age at exposure, at-
tained age and sex are included in I0. Therefore, a comparison 
of treatment plans with respect to second cancer incidence for 
one patient or a group of patients of the same population, can 
be performed simply by comparing the corresponding OEDs.
For the CT volume VCT where the dose is inhomoge-
neously distributed and a DVH was obtained, the OED was 
calculated [16] as 
 OED DVH (D D)∑1=CT iCT iCT iCT
i
−αDe
CT noCT(V )+ V
 (8),
where DVH(DiCT) is the volume which corresponds to the 
dose DiCT. We assumed here a linear-exponential dose-re-
sponse relation using a model parameter α = 0.08 Gy–1 [16, 18]. 
For a plateau dose-response relationship with a model param-
eter δ = 0.24 Gy–1, the OED is
         OED DVH (D )∑1=CT iCT iCT
i
−δD(1—e )/δ
CT noCT(V )+ V
 (9).
In VnoCT we assume scatter dose and neutron dose homoge-
neously distributed in the patient and can write for the lin-
ear-exponential dose-response curve
 OED D=noCT noCT
noCT−αDe
CT noCTV + V
noCTV
 (10)
and
 noCT−δD(1—e )/δOED D=noCT noCT
CT noCTV + V
noCTV
 (11)
using a plateau dose-response relationship, respectively. 
The risk for the occurrence of a secondary cancer after treat-
ment with radiation is then proportional to the sum of the OED 
inside and outside of the CT, respectively: 
  ( )I ≈ + OEDnoCTOEDCT  (12).
Results 
3-D Conformal Therapy 
The obtained OED for both the linear-exponential and pla-
teau dose-response with the corresponding standard deviation 
(variation between the different patients) is listed in Table 3 
and plotted in Figure 1. It is interesting to note that for conven-
tional 3-D conformal dose planning with 15 MV nearly 85% of 
the OED comes from the primary dose contribution and only 
the remaining 15% from X-ray scatter and neutrons.
IMRT
The OED for the IMRT treatment plans is increased com-
pared to the conventional four-field conformal treatments 
(Table 3). For the 6-MV IMRT plan the increase is close to 
15% using the linear-exponential dose-response (1% for the 
plateau dose-response). The part originating from X-ray and 
neutron scatter is decreased, since at such low photon energies 
nearly no neutrons are produced. However, the OED result-
ing from the primary dose field is increased by 25%, as during 
IMRT the volume receiving low dose is significantly higher. 
IMRT treatment plans with 15-MV and 18-MV photons have 
a 20% and 60% increased risk compared to the 3-D conformal 
plans. It should be noted, that for 15 MV and 18 MV the risk 
originating from the primary dose is less than the risk from the 
6-MV IMRT plan, because of the advantageous depth dose 
properties when using the higher energy. However, the neu-
tron dose contribution is remarkably increased when using 
higher photon energies for IMRT.
Proton Therapy
The use of spot-scanned protons reduces, independent of the 
dose-response curve used, the secondary cancer risk after 
Schneider U, et al. Secondary Cancer Incidence after Radiotherapy
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prostate therapy by a factor of 2 com-
pared to the 3-D conformal treatment 
plans. Although the neutron contribu-
tion is nearly as large as for the 15-MV 
IMRT plans, the dose advantage from 
the superior proton depth dose charac-
teristics is reducing the risk resulting 
from the primary dose by > 60%.
Discussion and Conclusion 
The results found in this study imply that 
IMRTs are related to an increased risk 
of secondary tumor induction. However, 
compared to previous publications on 
this topic [5, 19], we found only a moder-
ate increase of around 15% for prostate 
radiotherapy when a patient is treated 
with a 6-MV IMRT plan instead of a 
conventional 15-MV four-field plan. Our 
findings seem to be in contradiction to a 
recent publication of Followill et al. [5]. 
They found, for example, for 18-MV 
photons a 280% difference between ra-
diation-induced malignancies from con-
ventional radiation treatment compared 
to IMRT. One explanation for this is that Followill et al. [5] 
analyzed exclusively scattered X-ray and neutron radiation. 
However, they did not include the impact of the primary ra-
diation field on radiation-induced cancer. The primary radia-
tion field is responsible for the major part of radiation-induced 
cancers. Therefore, we believe that a fair comparison of radia-
tion-induced cancers resulting from different radiation treat-
ment techniques must include the impact of the primary radia-
tion field as well. For a conservative comparison with the 
Followill data the linear-exponential dose-response relation-
ship should be used, which gives highest weight to the scatter 
radiation. 
The usage of larger photon energies than 15 MV for IMRT 
can result in a significantly larger neutron component. For 
Tables 3a and 3b. Organ equivalent dose (OED) for different prostate radiation treatment 
techniques; a) for a linear-exponential and b) for a plateau dose-response relationship. 3-D: 
three-dimensional conformal radiotherapy; IMRT: intensity-modulated radiotherapy. 
Tabellen 3a und 3b. Organäquivalentdosis (OED) für verschiedene Bestrahlungstechniken der 
Prostata; a) für eine linear-exponentielle und b) für eine Plateau-Dosis-Wirkungs-Beziehung. 
3-D: dreidimensionale konformale Radiotherapie; IMRT: intensitätsmodulierte Radiotherapie. 
Treatment technique OED –  OED – X-ray OED – total σOED
 primary dose scatter and neutrons
 (Gy) (Sv) (Gy) (Gy)
a) Linear-exponential dose-response
3-D, 15 MV 0.33 0.06 0.40 0.09
3-D, 18 MV 0.33 0.16 0.49 0.09
IMRT, 6 MV 0.42 0.04 0.46 0.10
IMRT, 15 MV 0.39 0.09 0.48 0.09
IMRT, 18 MV 0.40 0.23 0.63 0.10
Protons 0.13 0.08 0.21 0.04
b) Plateau dose-response
3-D, 15 MV 0.44 0.06 0.50 0.12
3-D, 18 MV 0.42 0.15 0.57 0.12
IMRT, 6 MV 0.47 0.04 0.51 0.11
IMRT, 15 MV 0.42 0.09 0.51 0.09
IMRT, 18 MV 0.43 0.22 0.65 0.10
Protons 0.16 0.08 0.24 0.06
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Figures 1a and 1b. OED for different treatment techniques applied to prostate radiotherapy; a) for a linear-exponential, and b) for a plateau dose-
response relationship.  
Abbildungen 1a und 1b. OED für verschiedene Bestrahlungstechniken der Prostata; a) für eine linear-exponentielle und b) für eine Plateau-Do-
sis-Wirkungs-Beziehung. 
Figure 1a – Abbildung 1a        Figure 1b – Abbildung 1b 
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18-MV photons the dose from X-ray scatter and neutrons is 
approximately two to three times larger than compared to 
15-MV [4, 21]. It can be estimated that IMRT planned with 18 
MV would result in a 60% increased risk compared to the 3-D 
conformal plan and approximately a 30% increased risk com-
pared to the 15-MV IMRT plan. As a consequence, to reduce 
the risk, always the smallest possible photon energy should be 
chosen for IMRT. 
It should be noted that the low cancer incidence after 
proton radiotherapy is a consequence of the low neutron con-
tamination of the spot-scanning technique which requires no 
scattering, collimation or compensation, all of which could 
increase it up to a factor of 10 dependent on the specific beam 
line design.
In this work we have looked at several cases but only in-
vestigated one indication (prostate cancer). It is clearly diffi-
cult to draw general conclusions and extrapolate these find-
ings to other indications. However, as the major part to the 
risk of secondary cancer incidence results from the primary 
dose distribution, the findings of this work should also be ap-
plicable to other indications. This needs to be confirmed by 
performing similar calculations for other indications. 
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